Randomised Intergroup Trial of First line Treatment for young Low-Risk Patients (< 61 years) with Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL) with a CHOP-like Regimen with or without the Anti-CD20 Antibody Rituximab-6-Year Follow-up of the Mint Study of the Mabthera International Trial (MInT) Group

Pfreundschuh, M (author)

Kuhnt, E (author)

Trumper, L (author)

show more...

Osterborg, A (author)

Karolinska Institutet

Trneny, M (author)

Shepherd, L (author)

Gill, DS (author)

Walewski, J (author)

Pettengell, R (author)

Jager, U (author)

Zinzani, PL (author)

Shpilberg, O (author)

Kvaloy, S (author)

Hansen, M (author)

Stahel, R (author)

Milpied, N (author)

Lopez-Guillermo, A (author)

Grass, S (author)

Murawski, N (author)

Poschel, V (author)

Loffler, M (author)

show less...

 (creator_code:org_t)

2010

2010

English.

In: BLOOD. - 0006-4971. ; 116:21, s. 55-55

Related links:

http://kipublication...

• Conference paper (other academic/artistic)